3 citations
,
January 2023 in “Clinical cancer investigation journal” This theoretical study suggests that certain cannabinoid derivatives could potentially be effective as androgen receptor and 5α-reductase enzyme inhibitors, indicating they may be promising candidates for prostate cancer treatment based on their higher affinity to target proteins compared to standard drugs.
December 2023 in “International Journal of Pharmaceutics” This study developed innovative silica/natural polysaccharide hybrid nanoparticles encapsulating plant-derived 5-alpha-reductase inhibitors, reporting effective controlled release at hair follicle pH and lower cytotoxicity, suggesting a promising delivery system for antiandrogenic treatments.
November 2023 in “ACS Omega” This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.
27 citations
,
January 2017 in “Neuropsychopharmacology” This study found that acute sleep deprivation enhanced 5α-reductase expression and activity in the rat prefrontal cortex, and finasteride treatment reduced associated psychosis- and mania-like behaviors.
1 citations
,
October 2013 in “Our Dermatology Online” This study found that individuals in this Egyptian cohort carrying the leucine (L) allele of the 5-α reductase type II enzyme had a higher risk of developing androgenetic alopecia, which may be associated with oxidative stress.
This study reported that methanolic extracts from marine sponges, particularly Petrosia sp. and Agelas nakamurai, showed significant enzyme inhibitory activities, with Petrosia sp. exhibiting notable 5?-reductase inhibition.
May 2026 in “ACS Catalysis” In this study, researchers using QM/MM simulations identified key molecular motions and residue interactions in the enzyme SRD5A2 that significantly influence its catalytic efficiency, demonstrating that specific residues play critical roles in stabilizing transition states and reducing activation barriers.
18 citations
,
March 2020 in “Frontiers in Neuroendocrinology” This study suggests that synthetic steroid analogues or 5α-reductase modulation could be potential therapeutic strategies for nervous system disorders, but further research on their effects is necessary.
1 citations
,
October 2022 in “Iet Nanobiotechnology” This study explored a new dutasteride nanocarrier for alopecia therapy, concluding that ingredient concentration is key to achieving the optimal particle size, stability, and skin permeation for extended drug release.
49 citations
,
September 2015 in “Psychoneuroendocrinology” This study suggests that the 5α-reductase inhibitor finasteride modulates sensorimotor gating in rats by affecting D1 and D3 receptors, but not D2 receptors, with varying effects based on genetic strain.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” This study identified that derivatives 4, 4b, and 4c strongly inhibited the enzyme type 1 5α-reductase and decreased reproductive organ weights in hamsters, suggesting potential as prodrugs for prostate tumor growth inhibition.
16 citations
,
October 2017 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” This study found that dutasteride may offer neuroprotection in early-stage Parkinson's disease by preventing loss of striatal dopamine and altering steroid levels in MPTP-lesioned mice.
115 citations
,
March 2001 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism” This article reviews how different 5alpha-reductase and 3alpha-HSD enzymes impact androgen levels and highlights their potential as drug targets for androgen-related diseases, but provides no new experimental findings.
47 citations
,
June 2009 in “Journal of Biological Chemistry” This study found that finasteride competitively inhibits the enzyme AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator.
June 2021 in “International Journal of Ayurvedic Medicine” This study found that humulen, a phytoconstituent of Cyperus Rotundus Linn., showed the highest binding affinity in molecular docking with the 5 α reductase enzyme, suggesting potential anti-androgenic effects for hirsutism treatment.
November 2022 in “International Journal of Applied Pharmaceutics” This study found that phytosterols extracted from moringa seed oil may act as potential anti-alopecia agents by inhibiting the 5α-reductase enzyme, with ergostadienol showing particularly high affinity and stability in in silico simulations.
136 citations
,
March 1996 in “Journal of the American Chemical Society” This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.
10 citations
,
May 2010 in “Analytica Chimica Acta” This study reported the development of two highly sensitive ELISA assays to detect banned substances finasteride and dutasteride in human urine, offering better sensitivity than existing HPLC/MS/MS methods.
October 2013 in “DOAJ (DOAJ: Directory of Open Access Journals)” 
5 citations
,
July 2021 in “Endocrinology, diabetes & metabolism” This study found that glioblastoma cells express key enzymes involved in androgen synthesis, suggesting these enzymes might be potential targets for new therapeutic strategies.
5 citations
,
January 2022 in “Clinical cancer investigation journal” This study suggests that certain Dibenzo derivatives may be promising candidates for prostate cancer treatment due to their potential interactions with the androgen receptor and 5α-reductase enzyme.
17 citations
,
June 2012 in “European journal of medicinal chemistry” This study found that compounds 21–23 and 25 exhibited strong 5α-reductase II inhibition in vitro and significantly reduced rat prostate weight, performing comparably to finasteride.
37 citations
,
September 2018 in “Psychoneuroendocrinology” This study found that finasteride treatment in male rats led to enduring effects on depressive-like behavior, hippocampal neurogenesis and neuroinflammation, and gut microbiota composition after withdrawal.
18 citations
,
December 2005 in “Journal of Medicinal Chemistry” In this study, novel substituted benzoyl benzoic acids and phenylacetic acids were potent and selective inhibitors of human steroid 5alpha-reductase type 2, with one compound showing promising bioavailability in rats for potential clinical evaluation.
15 citations
,
May 2009 in “Steroids” This study found that progesterone derivatives with chlorine or bromine substituents were effective in inhibiting 5α-reductase activity in human prostate and exhibited antiandrogenic effects in hamster flank organs.
![Synthesis and 5α-Reductase Inhibitory Activity of 8-Substituted Benzo[ƒ]Quinolinones Derived from Palladium Mediated Coupling Reactions](/images/assets/2aedba8c-b0ac-4fa3-9ac7-9f375a016bba/small/15581.jpg)
14 citations
,
February 1998 in “Bioorganic & Medicinal Chemistry Letters” This study explored how modifying the 8-substituent of 8-bromobenzoquinolinone affects its selectivity in inhibiting both 5 alpha-reductase isozymes in the scalp.
1 citations
,
March 2021 in “F1000Research” This review discusses plant-derived phytochemicals, such as phytosterols, polyphenols, and fatty acids, as potential alternatives to 5-alpha-reductase inhibitors for prostate cancer treatment, highlighting their promising anti-cancer properties and potentially fewer side effects compared to conventional drugs.
64 citations
,
June 1995 in “Steroids” This review discusses biochemical studies on 5 alpha-reductase and its inhibitors, comparing IC50 and Ki values for various compounds, but reports no new experimental results.
33 citations
,
May 2013 in “Andrologia” This study identified several herbs, including Ganoderma lucidum and Urtica dioica, that showed promising 5α-reductase inhibitory activity suggesting potential use in managing androgenic disorders.
9 citations
,
October 1993 in “The Journal of Clinical Pharmacology” Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.